Branchenkontext
SELLAS Life Sciences [SLS]
Zuletzt aktualisiert 24 Jun 2026 @ 16:00 (Exchange is closed)
Letzter Kurs: $9.17
1.10%
4.08 (↓)
GaG Algo Score™
v1.0
Kurz
4.08 (↓)
Mittel
5.29 (↑)
Lang
5.00 (↑)
KAUF
60.00%
Rendite 44.76%
VERKAUF
63.27%
Rendite -26.46%
Linie
Pivot-Daten
Pivot-Statistik
| Kennzahl | Durchschnitt | Median | Std.-Abw. |
|---|---|---|---|
| Gewinn % | 57.17% | 31.13% | 64.29% |
| Verlust % | -24.87% | -23.20% | 11.88% |
| Dauer | 21.8d | 19d | 14.3d |
| Gefundene Pivots gesamt | 43 |
| Gewinn-/Verlustphasen | 42 (21 Gewinn / 21 Verlust) |
| Letzter Pivot | Top @ $9.07 am 2026-06-23 |
| Änderung seit letztem Pivot | $0.00 (0.00%) |
Nächste Pivot-Prognose Letzter Kurs: $9.17
| Erwarteter nächster Typ | Bottom |
| Erwarteter Preis (Durchschn.) | $6.81 |
| Erwarteter Preis (Median) | $6.97 |
| Erwarteter Preisbereich (~68%) | $5.74 - $7.89 |
| Änderung zum Durchschnittsziel | $-2.36 (-25.69%) |
| Erwartetes Datum (Durchschn.) | 2026-07-14 |
| Erwarteter Datumsbereich (~68%) | 2026-06-30 - 2026-07-29 |
| Basis | Based on 21 historical losses (Avg: -24.87%, Median: -23.20%, StdDev of Abs: 11.88%) and duration (Avg: 21.8 days, StdDev: 14.3 days) |
| Hinweis | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
SELLAS Life Sciences skyrockets 6.33%.
SELLAS Life Sciences (SLS) stock price jumped sharply on Tuesday after the stock rose $0.540 (6.33%) from the previous session on normal volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.40%.(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) Yesterday's trading volume was 7.21M shares, worth about $65.36M. This represents 895 847 shares less than the day before. Volume was close to the 10-day average of 6.75M shares.
SELLAS Life Sciences signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (46.7%), medium- (46.7%), and long-term (46.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
SELLAS Life Sciences Support & Resistance Levels
The stock is approaching the closest resistance level at $9.18. approximately $0.110 (1.21%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $9.31. On a fall back there will be support at $5 The dis das resistance s15 -
SELLAS Life Sciences Evaluation
- Kurz Score: 4.08
- Mittel Score: 5.29
- Lang Score: 5.00
Eigentümerfluss
GetAGraph InsiderPower
Transaktionen
48
Kaufkraft
17.42M
Verkaufskraft
513.6K
Zuverlässigkeit
94/100
Kauf / Verkauf
33.92
Hist. Korr.
0.05
Letztes Signal
Buy 2026-06-23
Director 25
Officer 16
Executive 7
2026-06-16
Stergiou Angelos M. Executive
Buy 1 065 000
2026-01-07
Varian John Director
Buy 50 000
2026-01-07
Van Nostrand Robert L Director
Buy 50 000
2026-01-07
Scheinberg David A Director
Buy 50 000
2026-01-07
Cicic Dragan Officer
Buy 300 000
2026-01-07
Burns John Thomas Officer
Buy 300 000
Beziehungsprofil
Korrelationsbild
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>2.05% <strong>$9.39</strong> paired level.</span>
Ereigniskontext
Volumen und Dividenden
Lange Volumenkorr.
0.39
Kurze Volumenkorr.
0.22
Positioning pressure
Short interest pressure
Short interest
57.87%
Of outstanding shares
Short float
58.07%
Of tradable float
Days to cover
4.42
Short interest divided by average volume
Squeeze probability
100.00%
+6.89% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Income profile
Dividend profile
Letzte Dividende
$0.420
2010-12-09
Nächste Dividende
$0
N/A
Avg. yearly yield
0.00%
Quarterly
Total paid
$0.570
2 payments
Sustainability
3.00
N/A
Growth potential
3.00
N/A
Direction
3.00
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2010-12-09 | $0.420 | 2010-12-20 |
| 2010-09-09 | $0.150 | 2010-09-22 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
-180.59%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q4/2025 | 2025-11-11 | - | - | - | - |
| Q3/2025 | 2025-08-12 | - | $-0.0800 | - | - |
| Q2/2025 | 2025-05-13 | $-0.0700 | $-0.100 | 30.00% | - |
| Q1/2025 | 2025-03-20 | $-0.0800 | $-0.110 | 27.27% | - |
| Q4/2024 | 2024-11-13 | $-0.100 | $-0.130 | 23.08% | - |
| Q3/2024 | 2024-08-13 | $-0.130 | $-0.160 | 18.75% | - |
| Q2/2024 | 2024-05-14 | $-0.210 | $-0.160 | -31.25% | - |
| Q1/2024 | 2024-03-28 | $-0.250 | $0.0867 | -388.45% | - |
Analyst view
Analyst targets
Consensus
$2.80
Median
$2.80
Low
$2.40
High
$3.20
News flow
Latest company news
Market coverage
benzinga.com SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move? May 20, 2026 globenewswire.com SELLAS Life Sciences to Participate in Upcoming Investor Conferences May 14, 2026 benzinga.com SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses May 13, 2026 globenewswire.com SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update May 12, 2026Company releases
Company context
Company profile
Börse:
NASDAQ
Sektor:
Healthcare
Branche:
Biotechnology
Currency
USD
SELLAS Life Sciences Group Inc a latestage clinical biopharmaceutical company focuses on the development of novel therapeutics for various cancer indications in the United States The companys lead product candidate is galinpepimutS GPS a peptide immunotherapy directed against the Wilms tumor 1 antigen and SLS009 tambiciclib a selective small molecule cyclindependent kinase 9 or CDK9 inhibitor It has a strategic collaboration with Merck Co Inc to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 12 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors GenFleet Therapeutics Shanghai Inc for the development and commercialization of GFH009 and Memorial Sloan Kettering Cancer Center for developing and commercializing MSKs WT1 peptide vaccine technology SELLAS Life Sciences Group Inc is headquartered in New York New York
Navigation